IGC Pharma (FRA:IGS1) 3-Year Revenue Growth Rate : -45.10% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma 3-Year Revenue Growth Rate?

IGC Pharma's Revenue per Share for the three months ended in Dec. 2023 was €0.00.

During the past 12 months, IGC Pharma's average Revenue per Share Growth Rate was 31.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -45.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -40.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was -34.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of IGC Pharma was 275.60% per year. The lowest was -65.50% per year. And the median was -40.25% per year.

Competitive Comparison of IGC Pharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, IGC Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where IGC Pharma's 3-Year Revenue Growth Rate falls into.

IGC Pharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

IGC Pharma (FRA:IGS1) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

IGC Pharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of IGC Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (FRA:IGS1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma (FRA:IGS1) Headlines

No Headlines